HUTCHMED (China) Limited (LON:HCM - Get Free Report) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 281.64 ($3.54) and traded as low as GBX 232 ($2.92). HUTCHMED shares last traded at GBX 238 ($2.99), with a volume of 10,578 shares changing hands.
HUTCHMED Trading Down 0.4 %
The company has a market cap of £2.03 billion, a PE ratio of -5,925.00 and a beta of 0.76. The company's 50 day simple moving average is GBX 279.70 and its two-hundred day simple moving average is GBX 281.33. The company has a debt-to-equity ratio of 11.78, a current ratio of 2.81 and a quick ratio of 2.97.
HUTCHMED Company Profile
(
Get Free Report)
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.
Recommended Stories
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
